Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

ClinicalTrials.gov ID: NCT01896297

Public ClinicalTrials.gov record NCT01896297. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy

Study identification

NCT ID
NCT01896297
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
63 participants

Conditions and interventions

Interventions

  • Pradaxa, dabigatran etexilate Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2013
Primary completion
Sep 30, 2015
Completion
Sep 30, 2015
Last update posted
Nov 29, 2016

2013 – 2015

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
1160.173.002 Boehringer Ingelheim Investigational Site Hot Springs Arkansas
1160.173.023 Boehringer Ingelheim Investigational Site Fremont California
1160.173.032 Boehringer Ingelheim Investigational Site Moreno Valley California
1160.173.034 Boehringer Ingelheim Investigational Site Oceanside California
1160.173.025 Boehringer Ingelheim Investigational Site Salinas California
1160.173.033 Boehringer Ingelheim Investigational Site San Pedro California
1160.173.024 Boehringer Ingelheim Investigational Site Wilmington Delaware
1160.173.010 Boehringer Ingelheim Investigational Site Washington D.C. District of Columbia
1160.173.020 Boehringer Ingelheim Investigational Site Jacksonville Florida
1160.173.036 Boehringer Ingelheim Investigational Site Jacksonville Florida
1160.173.012 Boehringer Ingelheim Investigational Site Largo Florida
1160.173.013 Boehringer Ingelheim Investigational Site Tampa Florida
1160.173.005 Boehringer Ingelheim Investigational Site Columbus Georgia
1160.173.018 Boehringer Ingelheim Investigational Site Springfield Missouri
1160.173.019 Boehringer Ingelheim Investigational Site St Louis Missouri
1160.173.026 Boehringer Ingelheim Investigational Site St Louis Missouri
1160.173.027 Boehringer Ingelheim Investigational Site Neptune City New Jersey
1160.173.014 Boehringer Ingelheim Investigational Site Wilmington North Carolina
1160.173.001 Boehringer Ingelheim Investigational Site Altoona Pennsylvania
1160.173.008 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
1160.173.037 Boehringer Ingelheim Investigational Site Lancaster South Carolina
1160.173.030 Boehringer Ingelheim Investigational Site Memphis Tennessee
1160.173.011 Boehringer Ingelheim Investigational Site Fort Worth Texas
1160.173.006 Boehringer Ingelheim Investigational Site Live Oak Texas
1160.173.021 Boehringer Ingelheim Investigational Site Norfolk Virginia
1160.173.035 Boehringer Ingelheim Investigational Site Waukesha Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01896297, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 29, 2016 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01896297 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →